BMAP-27 acetate
Based on 1 Customer Validation
BMAP-27 acetate is a cationic amphipathic α-helical antimicrobial peptide with anticancer activity. BMAP-27 acetate disrupts the integrity and permeability of cell membranes, leading to the leakage of intracellular DNA, proteins and alkaline phosphatase. BMAP-27 acetate increases intracellular ROS levels and reduces plasma endotoxin and TNF-α concentrations. BMAP-27 acetate can be used in studies related to Salmonella infection, breast cancer, lung cancer and obstructive jaundice.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Fòrmula: C158H263N45O27·xC2H4O2
- Peso molecular:3225.06 (free base)
-
Almacenamiento:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas TNF Receptor
More
Actividad biológica
BMAP-27 (2-4 μM) TFA potently inhibits the growth of S. aureus and E. coli with MIC values of 2-4 μM[2].
BMAP-27 (2-5 μM; 20-60 min) TFA rapidly kills S. aureus and E. coli, achieving near-complete bacterial death within 20 min at its MIC of 2 μM[2].
BMAP-27 TFA efficiently depolarises the cytoplasmic membranes of S. aureus and E. coli at concentrations lower than its MIC of 2-4 μM[2].
BMAP-27 (2 days) TFA exhibits strong dose-dependent cytotoxicity against human MDA-361 and A549 cancer cells, with IC50 values lower than its haemolytic activity IC50[2].
BMAP-27 (1 h) TFA exhibits moderate dose-dependent haemolytic activity against human red blood cells[2].
BMAP-27 (5-32 μM; 2-5 min) TFA potently disrupts anionic POPC/POPG (2:1) membranes, shows moderate disruption of zwitterionic POPC/cholesterol (4:1) membranes at high concentrations, and exhibits Phosphatidylserine (PS) (HY-A0183)-dependent membrane disruption that correlates with its anticancer activity[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (male, 25-35 g, bile duct ligation surgery for obstructive jaundice model)[3]
-
Dosage:1 mg/kg
-
Administration:i.p.; single dose
-
Result:Reduced plasma endotoxin levels to 496.3 EU/mL at 2 hours post-LPS, 438.5 EU/mL at 6 hours, and 0.097 EU/mL at 24 hours in sham-operated mice.
Reduced plasma endotoxin levels to 553.1 EU/mL at 2 hours post-LPS, 553.1 EU/mL at 6 hours, and 0.283 EU/mL at 24 hours in BDL mice.
Reduced plasma TNF-α levels to 0.45 ng/mL at 2 hours post-LPS in sham-operated mice.
Reduced plasma TNF-α levels to 0.80 ng/mL at 2 hours post-LPS, 0.24 ng/mL at 6 hours, and 0.08 ng/mL at 24-48 hours in BDL mice.
Reduced plasma IL-6 levels to 76.3 pg/mL at 2 hours post-LPS, 199.5 pg/mL at 6 hours, 187.3 pg/mL at 24 hours, and 88.1 pg/mL at 48 hours in BDL mice.
Reduced lethality to 15% over 48 hours in BDL mice.
Reduced bacterial colonization in peritoneal fluid to a mean of 5.5 × 101 CFU/mL in BDL mice.
Reduced blood culture positivity to 10% in BDL mice.
Showed no drug-related adverse effects or physiological parameter changes in non-LPS-exposed mice.
Chemical Information
-
Appearance Solid
-
Peso molecular 3225.06 (free base)
-
Fòrmula C158H263N45O27·xC2H4O2
-
Color White to off-white
-
Sequence
Gly-Arg-Phe-Lys-Arg-Phe-Arg-Lys-Lys-Phe-Lys-Lys-Leu-Phe-Lys-Lys-Leu-Ser-Pro-Val-Ile-Pro-Leu-Leu-His-Leu-NH2
-
Sequence Shortening
GRFKRFRKKFKKLFKKLSPVIPLLHL-NH2
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvente y solubilidad
DMSO : 100 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL; Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL; Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
Referencias
[1]. Xia R, et al. Insight into the inhibitory activity and mechanism of bovine cathelicidin BMAP 27 against Salmonella Typhimurium. Microbial pathogenesis. 2024 Feb;187:106540. [Content Brief]
[2]. Yang S, et al. Structural analysis and mode of action of BMAP-27, a cathelicidin-derived antimicrobial peptide. Peptides. 2019 Aug;118:170106. [Content Brief]
[3]. Ghiselli R, et al. Effects of the antimicrobial peptide BMAP-27 in a mouse model of obstructive jaundice stimulated by lipopolysaccharide. Peptides. 2006 Nov;27(11):2592-9. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
BMAP-27 acetate Related Classifications
HY-P5286A Related Classifications
Powered by Bioz